Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation iPSC-derived cell therapies
Company stage: Pre-clinical
Diseases (gene editing): Solid tumours, Multiple myeloma
Genome editing tool: TALEN, CRISPR
Funding stage: Private
Location: Aventura, Florida and New York, USA
Gene editing partnerships: Cellectis
Cytovia Therapeutics is a privately-held biotech company focused on the development of iPSC-derived natural killer (NK)- and CAR-NK cell therapies. The company uses CRISPR as well as TALEN technology, which it has licensed from Cellectis, for genomic editing of its NK cell candidates.